Article
Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
The oncologist - 1 Mar 2020
Gupta Rohan, Othman Tamer, Chen Chen, Sandhu Jaideep, Ouyang Ching, Fakih Marwan
Abstract excerpt
BACKGROUND: Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) tumor biopsy genomic profiling in metastatic colorectal cancer (mCRC) are limited. We aim to assess the concordance across overlapping genes tested in both F1 and G360 in patients with mCRC. MATERIALS AND METHODS: We retrospectively analyzed 75 patients with mCRC who underwent G360 and F1 testing. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.